Bli medlem
Bli medlem

Du är här

2016-10-18

Probi: Probi publishes prospectus supplement

PRESS RELEASE

Submitted for disclosure on 18 October 2016 at 12.00 (CET).

The information in this press release is not intended for
distribution, publication or public release, directly or indirectly,
in or into Australia, Canada, Japan, the United States or any other
jurisdiction where the publication or distribution of this press
release may be unlawful.

Probi AB (publ) ("Probi") has prepared a prospectus supplement in
addition to the prospectus which was approved and registered by the
Swedish Financial Supervisory Authority on 4 October 2016 regarding
invitation to subscribe for shares in the company and published on
the same day. The prospectus supplement has been prepared by reason
of the company's interim report for the period 1 January 2016 - 30
September 2016, which Probi published on 18 October 2016.

The prospectus supplement was approved and registered by the Swedish
Financial Supervisory Authority on 18 October 2016 and is available
on Probi's website www.probi.com and on the Swedish Financial
Supervisory Authority's website www.fi.se. The prospectus supplement
forms part of, and must be read together with, the prospectus.

Investors who, prior the publication of this prospectus supplement,
have applied for or otherwise given their consent to subscription of
shares in Probi's rights issue have, pursuant to chapter 2, section
34 of the Swedish Financial Instruments Trading Act (SFS 1991:980),
the right to withdraw their application or consent within two working
days from the publication of the prospectus supplement. Consequently,
the last day for withdrawal is 20 October 2016. Withdrawal shall be
made by a written notice to Handelsbanken Capital Markets, Emission,
SE-106 70 Stockholm, Sweden. Investors who have applied for
subscription of new shares in the rights issue through a nominee
shall contact their nominee regarding withdrawal. Applications that
are not withdrawn will remain binding and investors who want to
maintain their subscription of shares in the rights issue do not need
to take any action. For detailed terms and conditions as well as
other information about the rights issue, please refer to the
prospectus.

FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23, e-mail:
peter.nahlstedt@probi.se

(peter.nahlstedt@probi.se)Niklas Brandt, CFO, Probi, tel +46 46 286
89 26, e-mail: niklas.brandt@probi.se

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company that
develops effective and well-documented probiotics. Through its
world-leading research, Probi has created a strong product portfolio
in the gastrointestinal health and immune system niches. Probi's
products are available to consumers in more than 30 countries
worldwide. Probi's customers are leading food, health-product and
pharmaceutical companies in the Functional Food and Consumer
Healthcare segments. In 2015 Probi had sales of MSEK 216. The Probi
share is listed on Nasdaq Stockholm, Small Cap. Probi has about 4,400
shareholders. Read more at www.probi.se.

IMPORTANT NOTICE
The information in this press release does not contain or constitute
an offer to acquire, subscribe or otherwise trade in shares,
subscription rights or other securities in Probi. Any invitation to
the persons concerned to subscribe for shares in Probi is only made
through the prospectus which Probi published on 4 October 2016.

This press release may not be released, published or distributed,
directly or indirectly, in or into Australia, Japan, Canada, the
United States or any other jurisdiction where participation would
require additional prospectuses, registration or measures besides
those required by Swedish law. Nor may this press release be
distributed in or into such countries or any other country or
jurisdiction in which distribution requires such measures or
otherwise would be in conflict with applicable regulations. Any
failure to comply with the restrictions described may result in a
violation of applicable securities regulations.

No subscription rights, paid subscribed shares or shares in Probi have
been and will not be registered under the United States Securities
Act of 1933, as amended (the "Securities Act") or the securities
legislation of any state or other jurisdiction in the United States
and no subscription rights, paid subscribed shares or shares may be
offered, subscribed for, sold, resold, delivered or otherwise
transferred, directly or indirectly, in or into the United States
except under an available exemption from, or transaction not subject
to, the registration requirements under the Securities Act and in
compliance with the securities legislation in the relevant state or
any other jurisdiction of the United States. There is no intention to
register any securities referred to herein in the United States or to
make a public offering of the securities in the United States.

This press release contains certain forward-looking information that
reflects Probi's present view of future events as well as financial
and operational development. Words such as "intend", "assess",
"expect", "may", "plan", "believe", "estimate" and other expressions
entailing indications or predictions of future development or trends,
not based on historical facts, constitute forward-looking
information. Forward-looking information is inherently associated
with both known and unknown risks and uncertainties as it depends on
future events and circumstances. Forward-looking information is not a
guarantee of future results or development and actual outcomes may
differ materially from the statements set forth in the
forward-looking information.

-----------------------------------------------------------
http://feed.ne.cision.com/client/waymaker1/WOLReleaseFile.aspx?id=370467...
http://mb.cision.com/Main/1556/2103313/576399.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.